Cabozantinib, sold under the brand name of
Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer
and a second line treatment for renal cell carcinoma. It is a small molecule
inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and
RET. Discovered and developed by Exelixis Inc., its side-effects include
increased liver enzymes, diarrhea, low calcium, mouth sores, decreased appetite
and nausea.
In advanced
renal cell carcinoma, which is a form of kidney cancer, Cabozantinib is used in
those patients who have been previously treated with a type of cancer medicine
called ‘vascular endothelial growth factor (VEGF) inhibitor. It is also used in
patients who have not undergone previous treatment and whose cancer is at
moderate or high risk. In hepatocellular carcinoma, which is a form of liver
cancer, it is used in patients who have already been treated with the cancer
medicine such as Sorafenib. It is currently marketed in Europe and the U.S.
Request to Get the Sample Pages at:
This report
provides details of the drug and the API manufacturers across the 7 major
markets which includes U.S, EU5, and Japan. It includes the overview,
mechanism, regulatory milestones, strategic developments, the historical and
forecasted sales.
The pipeline
analysis of the drug by phase which would include the product description and
development activities including information about clinical results,
designations, collaborations, licensing, grants, technology and others.
